Sunny Pharmtech Inc. (TPEX:6676)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Research and Development of New Drugs and Generic Drugs	253.01M	418.01M	428.83M	359.59M	241.00M
Research and Development of New Drugs and Generic Drugs Growth	-39.47%	-2.52%	19.26%	49.21%	-42.61%
Total	253.01M	418.01M	428.83M	359.59M	241.00M
Total Growth	-39.47%	-2.52%	19.26%	49.21%	-42.61%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	103.83M	75.14M	72.63M	359.59M	241.00M
Taiwan Growth	38.18%	3.45%	-79.80%	49.21%	-42.61%
United States	146.57M	315.43M	347.15M	-	-
United States Growth	-53.53%	-9.14%	-	-	-
Others	2.61M	27.45M	9.05M	-	-
Others Growth	-90.49%	203.43%	-	-	-
Total	253.01M	418.01M	428.83M	359.59M	241.00M
Total Growth	-39.47%	-2.52%	19.26%	49.21%	-42.61%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 14, 2026

Data Sources Report a data error